Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$0.28 USD
-0.01 (-3.68%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.30 +0.02 (7.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SEEL 0.28 -0.01(-3.68%)
Will SEEL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SEEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SEEL
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
SEEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SEEL
Psychedelic drug developers could benefit from NIH funding for chronic pain
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
12 Health Care Stocks Moving In Monday's After-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023